Effient（ACS/急性冠症候群）：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 18
3.1.3 Prognosis 19
3.1.4 Quality of Life 20
3.2 Symptoms 20
4 Disease Management 22
4.1 Treatment Overview 22
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29
6 Effient (prasugrel) 34
6.1 Overview 34
6.2 Efficacy 36
6.3 Safety 37
6.4 SWOT Analysis 38
6.5 Forecast 38
7 Appendix 40
7.1 Bibliography 40
7.2 Abbreviations 45
7.3 Methodology 49
7.4 Forecasting Methodology 49
7.4.1 Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population 49
7.4.2 Diagnosed Acute Coronary Syndrome Patients 50
7.4.3 Percent Drug-Treated Patients 51
7.4.4 General Pricing Assumptions 51
7.4.5 Individual Drug Assumptions 53
7.4.6 Generic Erosion 53
7.5 Physicians and Specialists Included in this Study 54
7.6 About the Authors 57
7.6.1 Author 57
7.6.2 Reviewer 57
7.6.3 Global Head of Healthcare 58
7.7 About GlobalData 59
7.8 Disclaimer 59